Enlivex Ltd.

Informe acción NasdaqCM:ENLV

Capitalización de mercado: US$200.8m

Enlivex Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Enlivex disminuyan en un 147.8% al año. Se prevé que el BPA disminuya en un 149.7% al año.

Información clave

-147.8%

Tasa de crecimiento de los beneficios

-149.66%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs24.7%
Tasa de crecimiento de los ingresosn/a
Rentabilidad financiera futuran/a
Cobertura de analistas

Low

Última actualización23 Apr 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Artículo de análisis • Oct 07

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Artículo de análisis • Jun 19

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Mar 01

We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Artículo de análisis • Sep 13

Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Artículo de análisis • Apr 04

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Artículo de análisis • Dec 13

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Artículo de análisis • Jul 25

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Artículo de análisis • Apr 05

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Nov 16

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 30

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Summary Enlivex Therapeutics: The early results for Allocetra for sepsis (in humans) and solid tumors (in mice) look incredible. The share offering from 2021 shows a willingness to protect existing shareholders. All in all, the risk/reward profile justifies a small bet. Enlivex Therapeutics (ENLV) is a clinical stage pharmaceutical company developing a single drug candidate called Allocetra—an off-the-shelf, scalable, and affordable cell therapy which has been designed to reprogram macrophages in order to return them to their homeostatic state. It is currently being tested for life-threatening conditions such as sepsis and solid tumors, both as a standalone monotherapy and in combination with other therapies. The approach of ENLV is to target macrophages, a type of white blood cell that performs immune system functions such as removing dead cells from the body, engulfing and eliminating intrusive and harmful microbes that have entered the body, and activating other immune system cells. Sepsis is the body’s extreme response to an infection, whereby chemicals released in the blood to fight infection can trigger extreme inflammation in other parts of the body, potentially leading to organ failure. Like patients suffering from cancer, mortality rates for sepsis patients can be high. ENLV researchers believe that the macrophages of sepsis and solid tumor patients are out of their normal homeostatic state, and rather than engaging in anti-inflammation, pro-organ restoration, and anti-tumor activities, are instead engaging in pro-inflammation, pro-organ failure, and pro-tumor activities. The goal of Allocetra is to correct this imbalance and return macrophages to their homeostatic levels, which should reduce rates of drug resistance in patients and lead to better rates of disease resolution. Allocetra is a cell therapy, which refers to the practice of placing new cells into the patient’s body. After collecting cells from healthy donors, ENLV chemically modifies these donor cells using their proprietary process. The intent is to prompt the donor cells to send out an “eat me” signal, which is accomplished by expressing the biomarker phosphatidylserine, commonly known as “PtdSer.” Once the donor cells are placed into the patient’s body, the “eat me” signal attracts the macrophages in the surrounding inflamed area, which then engulf the donor cells. The engulfed donor cells then communicate with the macrophages while inside of them, and reprogram them in order to return them to their homeostatic state. ENLV’s method of communicating with the macrophages is proprietary, and forms the basis of their differentiated mechanism of action. To date, the only results in humans that we have for Allocetra were published on September 30, 2021 in the journal Frontiers In Immunology. As you can see in Table 1 on page 4, of the ten sepsis-treated patients, all of them lived, and their sepsis and organ dysfunction were resolved. Frontiers In Immunology; 9/30/21; pg 4 It does need to be pointed out that while the control group had a mortality rate of 27% (n=10/37), the phase 1b trial was run using a matched historical control. While this does not necessarily invalidate the results, using a matched historical control group is not as ideal as running a trial with simultaneous control and treatment groups. However, the currently-recruiting phase 2 sepsis trial will be a randomized, placebo-controlled, double-blind study. If the results can be replicated in phase 2, then this should alleviate investor concerns regarding the use of a historical control group in phase 1b. Thus far, all the solid tumor data we have is from animal models. But a quick glance at the results should make the potential impact of Allocetra very clear. ENLV ran the solid tumor study in mice suffering from mesothelioma, an aggressive and deadly form of cancer that occurs in the thin layer of tissue covering the majority of internal organs. In addition to Allocetra, the study incorporated the immune checkpoint inhibitor anti-CTLA4. The five groups analyzed were: mesothelioma (no treatment), mesothelioma + anti-CTLA4, mesothelioma + Allocetra (high dose), mesothelioma + anti-CTLA4 + Allocetra (low dose), and mesothelioma + anti-CTLA4 + Allocetra (high dose). On slide 30 of the company’s September 12, 2022 investor presentation, we can see clearly the encouraging results. By day 81, all eight of the mice in the no-treatment group had succumbed to the cancer. In the anti-CTLA4 group, only two of the eight mice were still alive, which was similar to the result of the high-dose Allocetra group (two of seven still alive). In the combo group of anti-CTLA4 + Allocetra (low dose), six of the nine mice were still alive. And finally, in the combo group of anti-CTLA4 + Allocetra (high dose), not only were all nine of the mice still alive, but all nine had a miraculous 100% cure rate. Company Presentation; 9/12/22; Slide 30 Any seasoned biotech investor knows that the number of companies that have shown very promising results in animal models that did not translate into the same results in humans are too numerous to count. Thus, these incredible results should be taken with a very large grain of salt. But a 100% survival rate and a 100% cure rate in the mouse model is startling, and clearly shows the synergistic potential of Allocetra when combined with another cancer-fighting agent. At a minimum, the mouse model results are certainly deserving of further investigation. On April 29, ENLV filed their 20-F Annual Report, which shows the number of ordinary shares beneficially owned by company insiders (it needs to be emphasized that the number of ordinary shares beneficially owned includes outstanding options and warrants to purchase ordinary shares). As of March 31, 2022, company insiders owned approximately 12% of the outstanding ordinary shares (see pg. 82), with Executive Chairman Shai Novak owning almost 7% on his own. 2021 20-F Annual Report Of Mr. Novak’s 1.3M potential shares, about 133K options have an exercise price of $2.69/share, and 174K have an exercise price of $3.66/share, with both exercise prices being below the current share price of about $4.00/share (as of September 29). However, Mr. Novak’s remaining options consist of 145K with an exercise price of $6.22/share, as well as 104K with an exercise price of $12.23/share, with both of these exercise prices being well above the current price. It would have been preferable if the exercise prices of all options would have been significantly higher than the current share price, as a low exercise price does not create a very high hurdle for management to reach in order to cash out. But for new shareholders at least, this level of potential insider ownership can be seen as a positive. One thing that investors should certainly like is the offering price of last year’s capital raise. The $10M offering announced on February 9, 2021 after-hours was for 500K shares at a price of $20.00/share. This came at a 17% discount to the previous day’s close of $24.00/share. However, the stock had closed at $13.05/share on February 2, and after positive COVID data was announced on February 3, proceeded to climb up to $24.00/share over the next few days. Viewed in this light, the offering price of $20.00/share and the 17% discount do not seem so unfair to existing shareholders. Furthermore, an expanded offering was announced later that same evening on February 9, 2021. The offering was expanded due to overwhelming demand, was also done at $20.00/share, and raised an additional $46M. They announced second quarter results on August 22, and as of June 30, had cash and cash equivalents of $63M, which management expects to last through 3Q2024. This works out to a quarterly cash burn of about $7M. With Allocetra development still being at such an early stage, it’s very unlikely that they will finance future clinical expenses via debt offerings.
Seeking Alpha • Sep 06

Enlivex to gets US patent covering use of cell therapy Allocetra

Enlivex Therapeutics (NASDAQ:ENLV) said the U.S. Patent and Trademark Office issued a notice of allowance for patent application covering methods of using Allocetra to inhibit or reduce cytokine release syndrome in patients undergoing chimeric antigen receptor (CAR) T-cell therapy. The company expects the new patent —  application number 15/551,284 — will be issued by the end of Q1 2023. The intellectual property protection is expected through at least 2036, the company said in a Sept. 6 press release. The company noted that Allocetra is being developed as a universal, off-the-shelf cell therapy aimed to reprogram macrophages into their homeostatic state.
Seeking Alpha • Aug 29

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Enlivex Therapeutics (NASDAQ:ENLV) said on Monday the Japanese patent office issued a Notice of Allowance that will provide the company with added intellectual property protection through at least 2037, with claims covering the use of pooled donor cells as source materials for cell therapy, Allocetra. The Company expects the new patent to be issued in Japan by the second quarter of 2023. Enlivex is developing Allocetra as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state.
Seeking Alpha • Aug 22

Envilex Therapeutics reports Q2 results

Envilex Therapeutics press release (NASDAQ:ENLV): Q2 Net loss of $9.9M As of June 30, 2022, Enlivex had cash, cash equivalents, and short-term deposits of $62.5 million.
Artículo de análisis • Jul 08

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 06

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Israel-based Enlivex Therapeutics (NASDAQ:ENLV) on Wednesday said the first patient had been dosed in its phase 1/2 clinical trial evaluating its cell therapy Allocetra in combination with chemotherapy to treat cancer of the peritoneum. ENLV stock +7.5% at $4.90 in afternoon trading. The early-to-mid stage trial is expected to enroll about 12 patients across four cohorts and will evaluate the safety and potential preliminary efficacy of Allocetra in combination with chemotherapy in peritoneal cancer patients. This is the initiation of the company's first oncology trial, according to ENLV CEO Oren Hershkovitz. The trial is taking place at Israel's Sheba Medical Center hospital.
Artículo de análisis • Mar 23

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Artículo de análisis • Nov 25

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Artículo de análisis • Aug 12

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Artículo de análisis • Apr 29

We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Jan 11

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Nov 19

Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?

If you want to know who really controls Enlivex Therapeutics Ltd. (NASDAQ:ENLV), then you'll have to look at the...

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:ENLV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2027N/A-25N/AN/A1
12/31/2026N/A-20N/AN/A1
12/31/2025N/A1,236-10-10N/A
9/30/2025N/A-13-12-12N/A
6/30/2025N/A-13-13-13N/A
3/31/2025N/A-14-13-13N/A
12/31/2024N/A-15-13-13N/A
9/30/2024N/A-19-14-14N/A
6/30/2024N/A-22-17-17N/A
3/31/2024N/A-26-22-22N/A
12/31/2023N/A-29-24-24N/A
9/30/2023N/A-27-26-23N/A
6/30/2023N/A-27-28-24N/A
3/31/2023N/A-30-34-26N/A
12/31/2022N/A-31-32-24N/A
9/30/2022N/A-29-32-26N/A
6/30/2022N/A-26-29-23N/A
3/31/2022N/A-19-21-18N/A
12/31/2021N/A-14-19-18N/A
9/30/2021N/A-16-18-17N/A
6/30/2021N/A-14-16-15N/A
3/31/2021N/A-14-15-14N/A
12/31/2020N/A-12-12-11N/A
9/30/2020N/A-9-7-7N/A
6/30/2020N/A-9-7-7N/A
3/31/2020N/A-8-5-5N/A
12/31/2019N/A-10-7-7N/A
9/30/2019N/A-9N/A-6N/A
6/30/2019N/A-7N/A-5N/A
3/31/2019N/A-7N/A-3N/A
12/31/2018N/A-5N/A-3N/A
9/30/2018N/A-4N/A-3N/A
12/31/2017N/A-3N/A-2N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de ENLV disminuyan en los próximos 3 años (-147.8% al año).

Beneficios vs. Mercado: Se prevé que los beneficios de ENLV disminuyan en los próximos 3 años (-147.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de ENLV disminuyan en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de ENLV crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: Se prevé que ENLV no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ENLV se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/07 00:46
Precio de las acciones al final del día2026/05/07 00:00
Beneficios2025/12/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Enlivex Ltd. está cubierta por 2 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Jason KolbertD. Boral Capital LLC.
Raghuram SelvarajuH.C. Wainwright & Co.